DCLK1 and colorectal carcinoma: Collectively, our data indicate that targeting DCLK1 kinase activity exert promising effects on CRC stemness, suggesting that DCLK1 may be a promising therapeutic target for aggressive CRC, and subsequent pharmacophore studies using the DCLK1 crystal structure would be valuable for new drug discovery.